Fan Genhao, Liu Menglin, Xing Zuoying, Chen Zhaoqi, Zhu Mingjun, Wang Yongxia
Henan University of Chinese Medicine, Zhengzhou, Henan 450000, China.
The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan 450000, China.
Evid Based Complement Alternat Med. 2021 Mar 26;2021:5591137. doi: 10.1155/2021/5591137. eCollection 2021.
To systematically evaluate the efficacy and safety of sofren injection combined with conventional Western medicine in the treatment of angina pectoris. Randomized controlled trials (RCTs) on the treatment of angina pectoris with sofren injection combined with Western medicine were collected by searching PubMed, the Cochrane Library, Embase, Web of Science, CNKI, Wanfang Database, Weipu Database, and China Biomedical Literature Service System (CBM) by computer with the retrieval time from establishment of database to August 2020. After literature screening according to the predetermined inclusion and exclusion criteria, data of eligible studies were extracted, and then, a meta-analysis was conducted with the RevMan 5.3 software. The results of meta-analysis showed that the combination of sofren injection and Western medicine improved the platelet aggregation rate of patients (MD = -5.53, 95% CI (-6.42, -4.64), < 0.00001), PAI-1 (SMD = -2.29, 95% CI (-2.57, -2.01), < 0.00001), TXB2 (MD = -11.91, 95% CI (-14.50, -9.32), < 0.00001), duration of angina attack (MD = -2.01, 95% CI (-3.14, -0.87), =0.0005), ECG symptoms (RR = 1.29, 95% CI (1.20, 1.37), < 0.00001), whole blood viscosity (MD = -1.07, 95% CI (-1.66, -0.48), =0.0004), plasma viscosity (MD = -0.27, 95% CI (-0.35, -0.20), < 0.00001), fibrinogen (MD = -0.67, 95% CI (-0.84, -0.50), < 0.00001), whole blood high shear viscosity (MD = -1.04, 95% CI (-1.30, -0.79), < 0.00001), whole blood low shear viscosity (MD = -2.03, 95% CI (-2.53, -1.53), < 0.00001), CRP (MD = -1.96, 95% CI (-3.01, -0.91), =0.0003), IL-6 (MD = -2.79, 95% CI (-4.02, -1.55), < 0.00001), and TNF- (MD = -17.34, 95% CI (-25.86, -8.81), < 0.00001) and better than the Western medicine group, and there was no statistical significance in the incidence of adverse reactions between the two groups (=0.48). The clinical application of sofren injection combined with conventional Western medicine in the treatment of angina pectoris is clear and safe, so it is recommended for clinical application.
系统评价苏芬注射液联合传统西药治疗心绞痛的疗效和安全性。通过计算机检索PubMed、Cochrane图书馆、Embase、Web of Science、中国知网、万方数据库、维普数据库和中国生物医学文献服务系统(CBM),收集关于苏芬注射液联合西药治疗心绞痛的随机对照试验(RCT),检索时间从数据库建立至2020年8月。根据预先设定的纳入和排除标准进行文献筛选,提取符合条件研究的数据,然后使用RevMan 5.3软件进行荟萃分析。荟萃分析结果显示,苏芬注射液联合西药可改善患者的血小板聚集率(MD = -5.53,95%CI(-6.42,-4.64),P < 0.00001)、纤溶酶原激活物抑制剂-1(SMD = -2.29,95%CI(-2.57,-2.01),P < 0.00001)、血栓素B2(MD = -11.91,95%CI(-14.50,-9.32),P < 0.00001)、心绞痛发作持续时间(MD = -2.01,95%CI(-3.14,-0.87),P = 0.0005)、心电图症状(RR = 1.29,95%CI(1.20,1.37),P < 0.00001)、全血黏度(MD = -1.07,95%CI(-1.66,-0.48),P = 0.0004)、血浆黏度(MD = -0.27,95%CI(-0.35,-0.20),P < 0.00001)、纤维蛋白原(MD = -0.67,95%CI(-0.84,-0.50),P < 0.00001)、全血高切黏度(MD = -1.04,95%CI(-1.30,-0.79),P < 0.00001)、全血低切黏度(MD = -2.03,95%CI(-2.53,-1.53),P < 0.00001)、C反应蛋白(MD = -1.96,95%CI(-3.01,-0.91),P = 0.0003)、白细胞介素-6(MD = -2.79,95%CI(-4.02,-1.55),P < 0.00001)和肿瘤坏死因子-α(MD = -17.34,95%CI(-25.86,-8.81),P < 0.00001),且优于西药组,两组不良反应发生率差异无统计学意义(P = 0.48)。苏芬注射液联合传统西药治疗心绞痛临床应用明确且安全,建议临床应用。